Collaboration
← Отчётные звонки
01
02
03
04 05 06
Тон
Капзатраты
A1 A2 A3
REGN
FY2026 Q2
Улучшается
Отчётный звонок Regeneron Pharmaceuticals, Inc.
Вывод Buzzberg
Sanofi collaboration repayment complete, boosting revenue from Q3.
Regeneron's Q2 2026 results showed strong growth driven by Dupixent, Eylea HD, and Libtayo, with a positive outlook and new pipeline catalysts. Management discusses early M&A interest and successful collaboration with Sanofi. FY2026 2Q revenue grew 17% to $4.3 billion driven by Dupixent, Eylea HD, and Libtayo.
Вывод Buzzberg Sanofi collaboration repayment complete, boosting revenue from Q3. Regeneron's Q2 2026 results showed strong growth driven by Dupixent, Eylea HD, and Libtayo, with a positive outlook and new pipeline catalysts. Management discusses early M&A interest and successful collaboration with Sanofi. FY2026 2Q revenue grew 17% to $4.3 billion driven by Dupixent, Eylea HD, and Libtayo. Читать полный анализСвернуть анализ
Regeneron's Q2 2026 results showed strong growth driven by Dupixent, Eylea HD, and Libtayo, with a positive outlook and new pipeline catalysts. Management discusses early M&A interest and successful collaboration with Sanofi. FY2026 2Q revenue grew 17% to $4.3 billion driven by Dupixent, Eylea HD, and Libtayo.
- Dupixent net sales reached $6 billion, up 38%, with Eylea HD up 52% to $596 million.
- Libtayo net sales up 29% to $489 million, capturing 20% of new-to-brand lung cancer share.
- CFO notes full Sanofi development balance repayment will boost Sanofi collaboration revenue from Q3 onwards.
Выручка$4.2907B+19% к/к
EPS$14.29+51% к/к
Валовая маржа86.56%Факт
Операционная маржа33.11%Факт
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
Regulatory
ILEA-HD pre-filled syringe approval targeted by year-end.
Pipeline
Long-acting IL-13 antibody shows prolonged half-life, expedited path.
Показать ещё 3 тезиса
Partnerships
Discussions with Sanofi to expand collaboration on follow-on assets.
Obesity
Obesity portfolio advancing with Phase III starts expected.
Pipeline
Factor XI program to initiate remaining Phase III studies this year.
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| Выручка | $4.2907B | +19% к/к |
| EPS | $14.29 | +51% к/к |
| Валовая маржа | 86.56% | Факт |
| Операционная маржа | 33.11% | Факт |
| Свободный денежный поток | $0.3343B | Факт |
| Капзатраты | $0.2402B | Факт |
Прогнозные данные
Прогноз компании
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| Свободный денежный поток | FY2026 | $1.4B | $1.4B | Обозначен |
AI, капзатраты и спрос
Оценка менеджмента
Upbeat
Management highlighted strong growth across key products, reiterated confidence in the pipeline and partnerships, and emphasized a broad, diversified portfolio and disciplined capital allocation.
Инвестиции и мощности
The company noted a temporary interruption in bulk manufacturing production at its Limerick, Ireland facility, which resumed to normal levels as of the end of the second quarter. No other significant capital expenditure or capacity investment details were discussed.
все упомянутые компании ниже: 2
Компаниис момента звонка
Партнёры
Партнёры
Chris Fenimore
Bayesian product royalties and profit share contributed a significant increase to other revenue, indicating underlying strength from the Bayer collaboration's portfolio.
Доказательства
“royalty income from Alaris combined with our share of profits from Arculus totaled $157 million, an increase of 44% versus the prior year.”
Партнёры
Dr. Leonard Schleifer
The full repayment of the Sanofi development balance will boost Sanofi collaboration revenue from Q3 onwards, with the company recording its full share of collaboration profits. — A new, higher-margin, recurring profit share kicks in following the repayment.
Доказательства
“productive early discussions with Sanofi to identify potential opportunities for further collaboration, including for several of Regeneron's Depixent follow-on programs.”
Внешние сигналы
Альфа цепочки поставок · 3с момента звонка
The full repayment of the Sanofi development balance will boost Sanofi collaboration revenue from Q3 onwards, with the company recording its full share of collaboration profits.
Доказательства
“Given full repayment of the Sanofi development balance, Starting in the third quarter, we expect Sanopi Collaboration Revenue to step up as we record our full share of collaboration profits.”
After two consecutive quarters of pressure, Regeneron's Limerick facility resumed normal production levels, alleviating unabsorbed manufacturing costs.
Доказательства
“Production at this facility resumed to normal levels as of the end of the second quarter.”
ILI-A HD sequentially declined 13-15% due to conversions and biosimilars, while HD is expected to grow low-to-mid teens on the back of share gains.
Доказательства
“we expect sequential quarterly demand declines in the low to mid-teens due to the factors mentioned as well as additional competition primarily from multiple Flippercept 2 mg biosimilar launches.”
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 2. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.